Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1997 Dec;73(866):785–793. doi: 10.1136/pgmj.73.866.785

Post-transplant hyperlipidaemia.

R M Jindal 1
PMCID: PMC2431514  PMID: 9497947

Abstract

The correction of post-transplant hyperlipidaemia warrants the judicious and timely use of pharmacological agents with dietary modification and exercise. Reduction in hyperlipidaemia may have some role in decreasing the incidence of chronic rejection of allografts. The awareness that the morbidity and mortality of atherosclerotic disease may be lowered by active intervention will result in a better quality of life for transplant recipients.

Full text

PDF
785

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amsterdam E. A., Hyson D., Kappagoda C. T. Nonpharmacologic therapy for coronary artery atherosclerosis: results of primary and secondary prevention trials. Am Heart J. 1994 Dec;128(6 Pt 2):1344–1352. doi: 10.1016/0002-8703(94)90258-5. [DOI] [PubMed] [Google Scholar]
  2. Anderson J. W., Johnstone B. M., Cook-Newell M. E. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995 Aug 3;333(5):276–282. doi: 10.1056/NEJM199508033330502. [DOI] [PubMed] [Google Scholar]
  3. Badalamenti S., Salerno F., Lorenzano E., Paone G., Como G., Finazzi S., Sacchetta A. C., Rimola A., Graziani G., Galmarini D. Renal effects of dietary supplementation with fish oil in cyclosporine-treated liver transplant recipients. Hepatology. 1995 Dec;22(6):1695–1671. [PubMed] [Google Scholar]
  4. Ballantyne C. M., Podet E. J., Patsch W. P., Harati Y., Appel V., Gotto A. M., Jr, Young J. B. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 1989 Jul 7;262(1):53–56. [PubMed] [Google Scholar]
  5. Berthoux F. C., Guerin C., Burgard G., Berthoux P., Alamartine E. One-year randomized controlled trial with omega-3 fatty acid-fish oil in clinical renal transplantation. Transplant Proc. 1992 Dec;24(6):2578–2582. [PubMed] [Google Scholar]
  6. Bierman E. L. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb. 1992 Jun;12(6):647–656. doi: 10.1161/01.atv.12.6.647. [DOI] [PubMed] [Google Scholar]
  7. Billiar T. R., Bankey P. E., Svingen B. A., Curran R. D., West M. A., Holman R. T., Simmons R. L., Cerra F. B. Fatty acid intake and Kupffer cell function: fish oil alters eicosanoid and monokine production to endotoxin stimulation. Surgery. 1988 Aug;104(2):343–349. [PubMed] [Google Scholar]
  8. Boushey C. J., Beresford S. A., Omenn G. S., Motulsky A. G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995 Oct 4;274(13):1049–1057. doi: 10.1001/jama.1995.03530130055028. [DOI] [PubMed] [Google Scholar]
  9. Bucala R., Makita Z., Vega G., Grundy S., Koschinsky T., Cerami A., Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9441–9445. doi: 10.1073/pnas.91.20.9441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bumgardner G. L., Wilson G. A., Tso P. L., Henry M. L., Elkhammas E. A., Davies E. A., Qiu W., Ferguson R. M. Impact of serum lipids on long-term graft and patient survival after renal transplantation. Transplantation. 1995 Dec 27;60(12):1418–1421. doi: 10.1097/00007890-199560120-00008. [DOI] [PubMed] [Google Scholar]
  11. Canner P. L., Berge K. G., Wenger N. K., Stamler J., Friedman L., Prineas R. J., Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986 Dec;8(6):1245–1255. doi: 10.1016/s0735-1097(86)80293-5. [DOI] [PubMed] [Google Scholar]
  12. Cattran D. C., Steiner G., Wilson D. R., Fenton S. A. Hyperlipidemia after renal transplantation: natural history and pathophysiology. Ann Intern Med. 1979 Oct;91(4):554–559. doi: 10.7326/0003-4819-91-4-554. [DOI] [PubMed] [Google Scholar]
  13. Curtis J. J., Galla J. H., Woodford S. Y., Lucas B. A., Luke R. G. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int. 1982 Jul;22(1):42–47. doi: 10.1038/ki.1982.130. [DOI] [PubMed] [Google Scholar]
  14. Cutts J. L., Bankhurst A. D. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol. 1990 Nov;145(2):244–252. doi: 10.1002/jcp.1041450208. [DOI] [PubMed] [Google Scholar]
  15. DeFronzo R. A., Goodman A. M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995 Aug 31;333(9):541–549. doi: 10.1056/NEJM199508313330902. [DOI] [PubMed] [Google Scholar]
  16. Deedwania P. C., Amsterdam E. A., Vagelos R. H. Evidence-based, cost-effective risk stratification and management after myocardial infarction. California Cardiology Working Group on Post-MI Management. Arch Intern Med. 1997 Feb 10;157(3):273–280. [PubMed] [Google Scholar]
  17. Dimény E., Fellström B., Larsson E., Tufveson G., Lithell H. Hyperlipoproteinemia in renal transplant recipients: is there a linkage with chronic vascular rejection? Transplant Proc. 1993 Apr;25(2):2065–2066. [PubMed] [Google Scholar]
  18. Dunn S. P., Falkenstein K., Lawrence J. P., Meyers R., Vinocur C. D., Billmire D. F., Weintraub W. H. Monotherapy with cyclosporine for chronic immunosuppression in pediatric liver transplant recipients. Transplantation. 1994 Feb 27;57(4):544–547. [PubMed] [Google Scholar]
  19. Elzinga L., Kelley V. E., Houghton D. C., Bennett W. M. Modification of experimental nephrotoxicity with fish oil as the vehicle for cyclosporine. Transplantation. 1987 Feb;43(2):271–274. doi: 10.1097/00007890-198702000-00021. [DOI] [PubMed] [Google Scholar]
  20. Endres S., Ghorbani R., Kelley V. E., Georgilis K., Lonnemann G., van der Meer J. W., Cannon J. G., Rogers T. S., Klempner M. S., Weber P. C. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989 Feb 2;320(5):265–271. doi: 10.1056/NEJM198902023200501. [DOI] [PubMed] [Google Scholar]
  21. Erickson K. L., Adams D. A., McNeill C. J. Dietary lipid modulation of immune responsiveness. Lipids. 1983 Jul;18(7):468–474. doi: 10.1007/BF02535787. [DOI] [PubMed] [Google Scholar]
  22. Escudero C., Alvarez L., de Haro J., González J., Alvarez M. V., Millán I., Jorge-Herrero E., Castillo-Olivares J. L. Prevention of arterial thrombosis by a monoclonal antibody against the 100 to 109 amino acid sequence stretch of the beta-subunit of the human platelet fibrinogen receptor: a comparative study with low dose aspirin. J Am Coll Cardiol. 1994 Feb;23(2):483–486. doi: 10.1016/0735-1097(94)90437-5. [DOI] [PubMed] [Google Scholar]
  23. Garg A., Grundy S. M. Management of dyslipidemia in NIDDM. Diabetes Care. 1990 Feb;13(2):153–169. doi: 10.2337/diacare.13.2.153. [DOI] [PubMed] [Google Scholar]
  24. Gokal R., Mann J. I., Moore R. A., Morris P. J. Hyperlipidaemia following renal transplantation. A study of the prevalence, 'natural history' and dietary treatment. Q J Med. 1979 Oct;48(192):507–517. [PubMed] [Google Scholar]
  25. Goren A., Stankiewicz H., Goldstein R., Drukker A. Fish oil treatment of hyperlipidemia in children and adolescents receiving renal replacement therapy. Pediatrics. 1991 Aug;88(2):265–268. [PubMed] [Google Scholar]
  26. Halloran P., Mathew T., Tomlanovich S., Groth C., Hooftman L., Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 1997 Jan 15;63(1):39–47. doi: 10.1097/00007890-199701150-00008. [DOI] [PubMed] [Google Scholar]
  27. Haq I. U., Jackson P. R., Yeo W. W., Ramsay L. E. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet. 1995 Dec 2;346(8988):1467–1471. doi: 10.1016/s0140-6736(95)92477-9. [DOI] [PubMed] [Google Scholar]
  28. Havel R. J., Rapaport E. Management of primary hyperlipidemia. N Engl J Med. 1995 Jun 1;332(22):1491–1498. doi: 10.1056/NEJM199506013322207. [DOI] [PubMed] [Google Scholar]
  29. Havel R. J. Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation. 1990 Feb;81(2):694–696. doi: 10.1161/01.cir.81.2.694. [DOI] [PubMed] [Google Scholar]
  30. Heitmann B. L., Lissner L., Sørensen T. I., Bengtsson C. Dietary fat intake and weight gain in women genetically predisposed for obesity. Am J Clin Nutr. 1995 Jun;61(6):1213–1217. doi: 10.1093/ajcn/61.6.1213. [DOI] [PubMed] [Google Scholar]
  31. Homan van der Heide J. J., Bilo H. J., Donker A. J., Wilmink J. M., Sluiter W. J., Tegzess A. M. The effects of dietary supplementation with fish oil on renal function and the course of early postoperative rejection episodes in cyclosporine-treated renal transplant recipients. Transplantation. 1992 Aug;54(2):257–263. [PubMed] [Google Scholar]
  32. Homan van der Heide J. J., Bilo H. J., Tegzess A. M., Donker A. J. The effects of dietary supplementation with fish oil on renal function in cyclosporine-treated renal transplant recipients. Transplantation. 1990 Mar;49(3):523–527. doi: 10.1097/00007890-199003000-00010. [DOI] [PubMed] [Google Scholar]
  33. Hricik D. E., O'Toole M. A., Schulak J. A., Herson J. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol. 1993 Dec;4(6):1300–1305. doi: 10.1681/ASN.V461300. [DOI] [PubMed] [Google Scholar]
  34. Hricik D. E. Posttransplant hyperlipidemia: the treatment dilemma. Am J Kidney Dis. 1994 May;23(5):766–771. doi: 10.1016/s0272-6386(12)70291-3. [DOI] [PubMed] [Google Scholar]
  35. Hsu I., Spinler S. A., Johnson N. E. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother. 1995 Jul-Aug;29(7-8):743–759. doi: 10.1177/106002809502907-818. [DOI] [PubMed] [Google Scholar]
  36. Hughes T. A., Gaber A. O., Amiri H. S., Wang X., Elmer D. S., Winsett R. P., Hathaway D. K., Hughes S. M. Kidney-pancreas transplantation. The effect of portal versus systemic venous drainage of the pancreas on the lipoprotein composition. Transplantation. 1995 Dec 27;60(12):1406–1412. [PubMed] [Google Scholar]
  37. Hwang D. Essential fatty acids and immune response. FASEB J. 1989 Jul;3(9):2052–2061. doi: 10.1096/fasebj.3.9.2501132. [DOI] [PubMed] [Google Scholar]
  38. Imagawa D. K., Dawson S., 3rd, Holt C. D., Kirk P. S., Kaldas F. M., Shackleton C. R., Seu P., Rudich S. M., Kinkhabwala M. M., Martin P. Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin. Transplantation. 1996 Oct 15;62(7):934–942. doi: 10.1097/00007890-199610150-00011. [DOI] [PubMed] [Google Scholar]
  39. Jacobs D., Blackburn H., Higgins M., Reed D., Iso H., McMillan G., Neaton J., Nelson J., Potter J., Rifkind B. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation. 1992 Sep;86(3):1046–1060. doi: 10.1161/01.cir.86.3.1046. [DOI] [PubMed] [Google Scholar]
  40. Jevnikar A. M., Petric R., Holub B. J., Philbrick D. J., Clark W. F. Effect of cyclosporine on plasma lipids and modification with dietary fish oil. Transplantation. 1988 Nov;46(5):722–725. doi: 10.1097/00007890-198811000-00018. [DOI] [PubMed] [Google Scholar]
  41. Jindal R. M. Pancreatic islet transplantation for diabetes. Postgrad Med J. 1994 Sep;70(827):665–666. doi: 10.1136/pgmj.70.827.665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Jindal R. M., Popescu I., Emre S., Schwartz M. E., Boccagni P., Meneses P., Mor E., Sheiner P., Miller C. M. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation. 1994 May 15;57(9):1395–1398. doi: 10.1097/00007890-199405150-00020. [DOI] [PubMed] [Google Scholar]
  43. Jindal R. M. Posttransplant diabetes mellitus--a review. Transplantation. 1994 Dec 27;58(12):1289–1298. [PubMed] [Google Scholar]
  44. Jindal R. M., Sidner R. A., Hughes D., Pescovitz M. D., Leapman S. B., Milgrom M. L., Lumeng L., Filo R. S. Metabolic problems in recipients of liver transplants. Clin Transplant. 1996 Apr;10(2):213–217. [PubMed] [Google Scholar]
  45. Kasiske B. L., Tortorice K. L., Heim-Duthoy K. L., Goryance J. M., Rao K. V. Lovastatin treatment of hypercholesterolemia in renal transplant recipients. Transplantation. 1990 Jan;49(1):95–100. doi: 10.1097/00007890-199001000-00021. [DOI] [PubMed] [Google Scholar]
  46. Katznelson S., Wilkinson A. H. HMGCoA reductase inhibitors and omega-3 fatty acids as adjunctive agents in maintenance immunosuppression after solid organ transplantation. Clin Transplant. 1995 Jun;9(3 Pt 1):197–200. [PubMed] [Google Scholar]
  47. Kelley V. E., Kirkman R. L., Bastos M., Barrett L. V., Strom T. B. Enhancement of immunosuppression by substitution of fish oil for olive oil as a vehicle for cyclosporine. Transplantation. 1989 Jul;48(1):98–102. doi: 10.1097/00007890-198907000-00023. [DOI] [PubMed] [Google Scholar]
  48. Kirk J. K., Dupuis R. E. Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient. Ann Pharmacother. 1995 Sep;29(9):879–891. doi: 10.1177/106002809502900911. [DOI] [PubMed] [Google Scholar]
  49. Kobashigawa J. A., Katznelson S., Laks H., Johnson J. A., Yeatman L., Wang X. M., Chia D., Terasaki P. I., Sabad A., Cogert G. A. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995 Sep 7;333(10):621–627. doi: 10.1056/NEJM199509073331003. [DOI] [PubMed] [Google Scholar]
  50. Krauss R. M., Chait A., Stone N. J. Soy protein and serum lipids. N Engl J Med. 1995 Dec 21;333(25):1715–1716. doi: 10.1056/NEJM199512213332515. [DOI] [PubMed] [Google Scholar]
  51. Krentz A. J., Dousset B., Mayer D., McMaster P., Buckels J., Cramb R., Smith J. M., Nattrass M. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. Diabetes. 1993 Dec;42(12):1753–1759. doi: 10.2337/diab.42.12.1753. [DOI] [PubMed] [Google Scholar]
  52. Li P. K., Mak T. W., Chan T. H., Wang A., Lam C. W., Lai K. N. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia. Transplantation. 1995 Oct 15;60(7):652–656. doi: 10.1097/00007890-199510150-00006. [DOI] [PubMed] [Google Scholar]
  53. Massy Z. A., Ma J. Z., Louis T. A., Kasiske B. L. Lipid-lowering therapy in patients with renal disease. Kidney Int. 1995 Jul;48(1):188–198. doi: 10.1038/ki.1995.284. [DOI] [PubMed] [Google Scholar]
  54. McDiarmid S. V., Farmer D. A., Goldstein L. I., Martin P., Vargas J., Tipton J. R., Simmons F., Busuttil R. W. A randomized prospective trial of steroid withdrawal after liver transplantation. Transplantation. 1995 Dec 27;60(12):1443–1450. doi: 10.1097/00007890-199560120-00013. [DOI] [PubMed] [Google Scholar]
  55. McDiarmid S. V., Gornbein J. A., Fortunat M., Saikali D., Vargas J. H., Busuttil R. W., Ament M. E. Serum lipid abnormalities in pediatric liver transplant patients. Transplantation. 1992 Jan;53(1):109–115. doi: 10.1097/00007890-199201000-00021. [DOI] [PubMed] [Google Scholar]
  56. McManus B. M., Malcom G., Kendall T. J., Gulizia J. M., Wilson J. E., Winters G., Costanzo M. R., Thieszen S., Radio S. J. Lipid overload and proteoglycan expression in chronic rejection of the human transplanted heart. Clin Transplant. 1994 Jun;8(3 Pt 2):336–340. [PubMed] [Google Scholar]
  57. Miller L. W. Steroid withdrawal in heart transplantation. J Heart Lung Transplant. 1992 Mar-Apr;11(2 Pt 2):401–402. [PubMed] [Google Scholar]
  58. Morrisett J. D., Northrup S. R., Gotto A. M., Jr, Starzl T. E., Venkataramanan R., Van Thiel D., Murase N. Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. Transplant Proc. 1991 Dec;23(6):3185–3187. [PubMed] [Google Scholar]
  59. Munoz S. J., Deems R. O., Moritz M. J., Martin P., Jarrell B. E., Maddrey W. C. Hyperlipidemia and obesity after orthotopic liver transplantation. Transplant Proc. 1991 Feb;23(1 Pt 2):1480–1483. [PubMed] [Google Scholar]
  60. Murgia M. G., Jordan S., Kahan B. D. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int. 1996 Jan;49(1):209–216. doi: 10.1038/ki.1996.28. [DOI] [PubMed] [Google Scholar]
  61. Muñoz S. J. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: pathogenesis, diagnosis, and management. Liver Transpl Surg. 1995 Sep;1(5 Suppl 1):29–38. [PubMed] [Google Scholar]
  62. Nelson J., Beauregard H., Gélinas M., St-Louis G., Daloze P., Smeesters C., Corman J. Rapid improvement of hyperlipidemia in kidney transplant patients with a multifactorial hypolipidemic diet. Transplant Proc. 1988 Dec;20(6):1264–1270. [PubMed] [Google Scholar]
  63. Norman D. J., Illingworth D. R., Munson J., Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med. 1988 Jan 7;318(1):46–47. doi: 10.1056/NEJM198801073180110. [DOI] [PubMed] [Google Scholar]
  64. Oliver M. F. Statins prevent coronary heart disease. Lancet. 1995 Nov 25;346(8987):1378–1379. doi: 10.1016/s0140-6736(95)92399-3. [DOI] [PubMed] [Google Scholar]
  65. Otto D. A., Kahn D. R., Hamm M. W., Forrest D. E., Wooten J. T. Improved survival of heterotopic cardiac allografts in rats with dietary n-3 polyunsaturated fatty acids. Transplantation. 1990 Aug;50(2):193–198. doi: 10.1097/00007890-199008000-00004. [DOI] [PubMed] [Google Scholar]
  66. Padbury R. T., Gunson B. K., Dousset B., Hubscher S. G., Buckels J. A., Neuberger J. M., Elias E., McMaster P. Steroid withdrawal from long-term immunosuppression in liver allograft recipients. Transplantation. 1993 Apr;55(4):789–794. doi: 10.1097/00007890-199304000-00020. [DOI] [PubMed] [Google Scholar]
  67. Palombo J. D., Lopes S. M., Zeisel S. H., Jenkins R. L., Albers J. J., Blackburn G. L., Bistrian B. R. Effectiveness of orthotopic liver transplantation on the restoration of cholesterol metabolism in patients with end-stage liver disease. Gastroenterology. 1987 Dec;93(6):1170–1177. doi: 10.1016/0016-5085(87)90241-1. [DOI] [PubMed] [Google Scholar]
  68. Pedersen T. R. Lowering cholesterol with drugs and diet. N Engl J Med. 1995 Nov 16;333(20):1350–1351. doi: 10.1056/NEJM199511163332010. [DOI] [PubMed] [Google Scholar]
  69. Perez R. V., Alexander J. W. Immune regulation by lipids. Transplant Proc. 1988 Dec;20(6):1162–1165. [PubMed] [Google Scholar]
  70. Perez R. V., Munda R., Alexander J. W. Dietary immunoregulation of transfusion-induced immunosuppression. Transplantation. 1988 Mar;45(3):614–617. doi: 10.1097/00007890-198803000-00022. [DOI] [PubMed] [Google Scholar]
  71. Pirsch J. D., Armbrust M. J., Knechtle S. J., Reed A., D'Alessandro A. M., Sollinger H. W., Belzer F. O. Effect of steroid withdrawal on hypertension and cholesterol levels in living related recipients. Transplant Proc. 1991 Feb;23(1 Pt 2):1363–1364. [PubMed] [Google Scholar]
  72. Pyke D. Pancreas transplantation. Diabetes Metab Rev. 1991 Mar;7(1):3–14. doi: 10.1002/dmr.5610070104. [DOI] [PubMed] [Google Scholar]
  73. Raine A. E., Carter R., Mann J. I., Chapman J. R., Morris P. J. Increased plasma LDL cholesterol after renal transplantation associated with cyclosporine immunosuppression. Transplant Proc. 1987 Feb;19(1 Pt 2):1820–1821. [PubMed] [Google Scholar]
  74. Ratcliffe P. J., Firth J. D., Higgins R. M., Smith B., Gray D. W., Morris P. J. Randomized controlled trial of complete steroid withdrawal in renal transplant patients receiving triple immunosuppression. Transplant Proc. 1993 Feb;25(1 Pt 1):590–590. [PubMed] [Google Scholar]
  75. Reaven G. M., Laws A. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia. 1994 Sep;37(9):948–952. doi: 10.1007/BF00400953. [DOI] [PubMed] [Google Scholar]
  76. Reaven G. M., Laws A. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia. 1994 Sep;37(9):948–952. doi: 10.1007/BF00400953. [DOI] [PubMed] [Google Scholar]
  77. Reisman L., Lieberman K. V., Burrows L., Schanzer H. Follow-up of cyclosporine-treated pediatric renal allograft recipients after cessation of prednisone. Transplantation. 1990 Jan;49(1):76–80. doi: 10.1097/00007890-199001000-00017. [DOI] [PubMed] [Google Scholar]
  78. Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M., Wun C. C. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]
  79. Sandborn W. J., Hay J. E., Porayko M. K., Gores G. J., Steers J. L., Krom R. A., Wiesner R. H. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology. 1994 Apr;19(4):925–932. [PubMed] [Google Scholar]
  80. Savage P. J. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann Intern Med. 1996 Jan 1;124(1 Pt 2):123–126. doi: 10.7326/0003-4819-124-1_part_2-199601011-00008. [DOI] [PubMed] [Google Scholar]
  81. Schreiner G. F., Flye W., Brunt E., Korber K., Lefkowith J. B. Essential fatty acid depletion of renal allografts and prevention of rejection. Science. 1988 May 20;240(4855):1032–1033. doi: 10.1126/science.3285468. [DOI] [PubMed] [Google Scholar]
  82. Schrör K., Löbel P., Steinhagen-Thiessen E. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia. Eicosanoids. 1989;2(1):39–45. [PubMed] [Google Scholar]
  83. Shepherd J., Cobbe S. M., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov 16;333(20):1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
  84. Stern M. P. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med. 1996 Jan 1;124(1 Pt 2):110–116. doi: 10.7326/0003-4819-124-1_part_2-199601011-00006. [DOI] [PubMed] [Google Scholar]
  85. Superko H. R., Haskell W. L., Di Ricco C. D. Lipoprotein and hepatic lipase activity and high-density lipoprotein subclasses after cardiac transplantation. Am J Cardiol. 1990 Nov 1;66(15):1131–1134. doi: 10.1016/0002-9149(90)90517-5. [DOI] [PubMed] [Google Scholar]
  86. Superko H. R., Krauss R. M. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation. 1994 Aug;90(2):1056–1069. doi: 10.1161/01.cir.90.2.1056. [DOI] [PubMed] [Google Scholar]
  87. Sweny P., Wheeler D. C., Lui S. F., Amin N. S., Barradas M. A., Jeremy J. Y., Mikhailidis D. P., Varghese Z., Fernando O. N., Moorhead J. F. Dietary fish oil supplements preserve renal function in renal transplant recipients with chronic vascular rejection. Nephrol Dial Transplant. 1989;4(12):1070–1075. [PubMed] [Google Scholar]
  88. Taylor D. O., Thompson J. A., Hastillo A., Barnhart G., Rider S., Lower R. R., Hess M. L. Hyperlipidemia after clinical heart transplantation. J Heart Transplant. 1989 May-Jun;8(3):209–220. [PubMed] [Google Scholar]
  89. Urakaze M., Hamazaki T., Kashiwabara H., Omori K., Fischer S., Yano S., Kumagai A. Favorable effects of fish oil concentrate on risk factors for thrombosis in renal allograft recipients. Nephron. 1989;53(2):102–109. doi: 10.1159/000185720. [DOI] [PubMed] [Google Scholar]
  90. Vathsala A., Weinberg R. B., Schoenberg L., Grevel J., Goldstein R. A., Van Buren C. T., Lewis R. M., Kahan B. D. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation. 1989 Jul;48(1):37–43. doi: 10.1097/00007890-198907000-00009. [DOI] [PubMed] [Google Scholar]
  91. Yoshimura N., Oka T., Okamoto M., Ohmori Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation. 1992 Jan;53(1):94–99. doi: 10.1097/00007890-199201000-00018. [DOI] [PubMed] [Google Scholar]
  92. van der Heide J. J., Bilo H. J., Donker J. M., Wilmink J. M., Tegzess A. M. Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med. 1993 Sep 9;329(11):769–773. doi: 10.1056/NEJM199309093291105. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES